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To the Editor:
We read with interest the work by
Sandler et al.1 recently appeared in the
September issue of the Journal of Tho-
racic Oncology, confirming a better sur-
vival when bevacizumab is added to car-
boplatin plus paclitaxel in the treatment
of advanced non-small cell lung cancer
(NSCLC), particularly adenocarcinoma.
This work prompted us to spend a word of
caution on the proper definition of histol-
ogy when preparing such clinical studies
and to suggest a practical proposal on the
correct use of histology when dealing with
small biopsies and cytology in NSCLC.
It is widely accepted that histologic
subtyping of NSCLC is mandatory when
using some new drugs, namely bevaci-
zumab and pemetrexed, in the treatment
of patients with advanced NSCLC.2 How-
ever, in the aforementioned work by San-
dler et al.,1 in our opinion, more than 30%
of enrolled patients had a controversial
diagnosis for the following reasons. First,
in advanced NSCLC, pathologists gener-
ally deal with a small biopsy or cytology,
and this fact precludes the use of terms
such as bronchioloalveolar adenocarci-
noma (formerly lepidic predominant inva-
sive adenocarcinoma in the new World
Health Organization [WHO], Interna-
tional Association for the Study of Lung
Cancer [IASLC], American Thoracic So-
ciety [ATS], and European Respiratory
Society [ERS] classification of pulmonary
adenocarcinoma)3 or large cell carci-
noma. In fact, the correct use of these
histologic entities requires a surgical
specimen. Second, it is unclear the
meaning of the term “other” (3.9% of
the entire series), which may indicate
many different entities, such as carci-
noid tumors, salivary gland type carci-
nomas, or merely representing a poorly
differentiated NSCLC, not otherwise
specified.
It is not our purpose to discuss the
validity of the important work of Sandler
et al.,1 but rather to take the opportunity
here to clarify an underscored point when
organizing clinical trial, in light of the
emerging role of histologic type in assess-
ing the efficacy of new pharmaceutical
agents. On one side, oncologists are ask-
ing pathologists a huge effort in discrimi-
nating histologic type of NSCLC in rou-
tine practice, but on the other side, in
clinical trials on NSCLC, several inappro-
priate histologic terms are used widely.
On the basis of the criteria of the
2004-WHO classification of lung tumors
and personal experience, we propose a list
of histologic terms in Table 1 that should
be used and avoided in clinical trials on
advanced NSCLC, when just a minute
tumor sample or cytology is available.
This simple proposal is sufficiently
solid for histology assessment of ad-
vanced NSCLC and may be very helpful
when used in enrolling patients in a clin-
ical trial on advanced NSCLC, also per-
mitting more reproducible results when
comparing data from different trials on the
value of histology in NSCLC treatments.
In our opinion, the diagnosis of
bronchioloalveolar adenocarcinoma and
large cell carcinoma should be abandoned
in clinical trials, whereas the use of the
term NSCLC could be maintained, al-
though limited to poorly differentiated
NSCLC in which special stains (histo-
chemistry and particularly immunohisto-
chemistry) failed to find out a specific
differentiation.
In summary, NSCLC histologic
subtyping may have a clear-cut impact in
determining drug efficacy and toxicity and
in reducing the costs for the National
Health Services,4 but data on histologic
type reported in clinical trials often do not
meet the criteria of the WHO classifica-
tion of lung tumors. Then, it could be
reasonable to adopt a common and re-
producible method to insert histology in
future clinical trials, when histologic def-
inition of NSCLC may be a key variable
in univariate or multivariate statistical
analyses, as well established in consider-
ing data on clinical response according to
consolidated systems of evaluation.5
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TABLE 1. Histologic Types Terminology
for Clinical Trials on Advanced Lung
Carcinoma
To Be Used To Be Avoided
Adenocarcinoma Large cell carcinomaa
Squamous cell carcinoma Bronchioloalveolar
adenocarcinomaSmall cell carcinoma
Carcinoid tumors
Salivary gland type
carcinomab
NSCLCc
a Sometimes, the diagnosis of large cell neuroendo-
crine carcinoma can be suggested based on small biopsies
and cytology, but this is controversial and requires further
studies.
b The exact entity (e.g., mucoepidermoid carcinoma,
adenoid cystic carcinoma, epithelial-myoepithelial carci-
noma) should be specified whenever possible.
c To be used only when special stains or central pathol-
ogy review failed to find out tumor cell differentiation.
NSCLC, non-small cell lung carcinoma.
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